Abstract #1842

Development and external validation of IMPROD biparametric MRI-based nomogram for the prediction of prostate biopsy outcome in men with a clinical suspicion of prostate cancer (IMPROD and MULTI-IMPROD trials, #opensourcetrial)

Ivan Jambor^1,2, Ileana Montoya Perez¹, Janne Verho¹, Otto Ettala³, Juha Knaapila³, Pekka Taimen¹, Kari Syvänen³, Aida Kiviniemi¹, Esa Kähkönen³, Marjo Seppänen⁴, Antti Rannikko⁵, Outi Oksanen⁵, Jarno Riikonen⁶, Sanna-Mari Vimpeli⁶, Tommi Kauko³, Harri Merisaari¹, Tapio Pahikkala¹, Markku Kallajoki³, Tuomas Mirtti⁷, Jani Saunavaara³, Peter J Boström³, and Hannu Aronen¹

¹University of Turku, Turku, Finland, ²Icahn School of Medicine at Mount Sinai, New York, NY, United States, ³Turku University Hospital, Turku, Finland, ⁴Satakunta Central Hospital, Pori, Finland, ⁵Helsinki University Hospital, Helsinki, Finland, ⁶Tampere University Hospital, Tampere, Finland, ⁷University of Helsinki, Helsinki, Finland

Nomograms for prediction of prostate biopsy outcomes incorporating qualitative and quantitative findings of IMPROD biparametric MRI (IMPROD bpMRI consists of T2 weighted imaging and three separate DWI acquisitions) were developed using data of 161 men enrolled as a part of the single-institutional IMPROD (NCT01864135) trial and externally validated in 338 men enrolled as a part of the multi-institutional MULTI-IMPROD(NCT02241122) trial. A nomogram using IMPROD bpMRI findings had area under the curve values (95% confidence interval) of 0.92 (0.88-0.96), and 0.88 (0.84-0.92) in the development and validation cohorts, respectively, for the detection of prostate cancer with Gleason score 3+4 or higher.

This abstract and the presentation materials are available to members only; a login is required.

Join Here